Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

Blood Cancer Journal

Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma

British Journal of Haematology

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

Cureus

Rare extramedullary manifestations of multiple myeloma: a case series involving the thyroid, pleura, and skin

US Food & Drug Administration

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

Clinica Chimica Acta; International Journal of Clinical Chemistry

Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

New England Journal of Medicine

Teclistamab in multiple myeloma with one to three previous lines of therapy

Annals of Medicine and Surgery

Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study

The Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

American Journal of Blood Research

Therapy-related B-cell acute lymphoblastic leukemia after treatment for multiple myeloma